Institute of Translational Medicine, Shanghai University, Shanghai, China.
Department of Pharmacy, Shanghai East Hospital, Tongji University, Shanghai, China.
Curr Pharm Des. 2022;28(34):2825-2834. doi: 10.2174/1381612828666220902123755.
Acute kidney injury (AKI) is closely linked to the pathogenesis of sepsis. Oxidative stress can affect the development of AKI by increasing damage to renal tubular epithelial cells. Astragaloside IV (AS-IV) is a natural saponin widly verified beneficial for ameliorating sepsis-induced kidney injury. However, the underlying mechanisms of AS-IV on relieving oxidative stress in renal tubular epithelial cells are yet to be established.
We aimed to investigate whether AS-IV could attenuate mitochondrialdysfunction and apoptosis in renal tubular epithelial cells and reveal its underlying mechanisms.
For the in vivo study, mice were divided into four groups (n=6): sham+saline, CLP+saline, CLP+ASIV- low dosage (5 mg/kg), CLP+AS-IV-high dosage (10 mg/kg), After 6 h or 24 h of treatment, the renal injuries were assessed based on related parameters of blood, protein and histopathological examination. Immunohistochemistry and ELISA were used to examine renal function. The molecular mechanism of AS-IV inhibited apoptosis and mitochondrial damage were monitored by flow cytometry and western blot analysis in HK-2 cells.
We found that AS-IV ameliorates renal vacuolization, brush border loss, mitochondrial ultrastructure changes in sepsis-induced AKI, and the apoptosis and oxidative damage were greatly mitigated by AS-IV (10 mg/kg)-treated group. Abnormal changes in mitochondrial morphology and mitochondrial membrane potential were alleviated, and the expression of mitochondrial complex protein I (NDUFB8) and mitochondrial complex protein II (SDHB8) increased with (10 mg/kg)-treated group. Tubular epithelial cell apoptosis in AS-IV (20 μM)-treated cells was reduced by the Bax and cleaved caspase3 pathway.
These studies demonstrated that AS-IV protects against sepsis-induced kidney tubular injury by alleviating oxidative stress, mitochondrial dysfunction possibly associated with the restored cleaved caspase3 pathway.
急性肾损伤(AKI)与脓毒症的发病机制密切相关。氧化应激可通过增加肾管状上皮细胞损伤而影响 AKI 的发展。黄芪甲苷(AS-IV)是一种天然皂苷,已被广泛证实可改善脓毒症引起的肾损伤。然而,AS-IV 缓解肾管状上皮细胞氧化应激的潜在机制尚不清楚。
本研究旨在探讨 AS-IV 是否可以减轻肾管状上皮细胞的线粒体功能障碍和凋亡,并揭示其潜在机制。
在体内研究中,将小鼠分为四组(n=6):假手术+生理盐水组、盲肠结扎穿孔(CLP)+生理盐水组、CLP+AS-IV 低剂量(5mg/kg)组、CLP+AS-IV 高剂量(10mg/kg)组。在治疗后 6 小时或 24 小时,根据血液、蛋白和组织病理学检查的相关参数评估肾损伤。免疫组织化学和 ELISA 用于检测肾功能。通过流式细胞术和 Western blot 分析监测 AS-IV 抑制凋亡和线粒体损伤的分子机制。
我们发现 AS-IV 改善了脓毒症诱导的 AKI 中的肾空泡化、刷状缘丢失、线粒体超微结构变化,并且 AS-IV(10mg/kg)治疗组大大减轻了细胞凋亡和氧化损伤。异常的线粒体形态和线粒体膜电位变化得到缓解,线粒体复合物蛋白 I(NDUFB8)和线粒体复合物蛋白 II(SDHB8)的表达增加。AS-IV(20μM)处理组降低了肾小管上皮细胞中的 Bax 和 cleaved caspase3 通路的细胞凋亡。
这些研究表明,AS-IV 通过减轻氧化应激、线粒体功能障碍来保护脓毒症引起的肾脏管状损伤,这可能与恢复的 cleaved caspase3 通路有关。